Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Cancer biology

T cells team up with chemotherapy

Immune cells called T cells could make some chemotherapies more effective against ovarian cancer.

Rebecca Liu and Weiping Zou of the University of Michigan in Ann Arbor and their colleagues studied human ovarian cancer cells in culture. They showed that fibroblasts — connective-tissue cells found in and around tumours — made tumour cells resistant to the platinum-based chemotherapy drug cisplatin by reducing DNA-damaging platinum levels in cancer cells. T cells in the tumour's environment, however, restored the drug's tumour-killing abilities by producing a protein called interferon-γ, which alters certain metabolic pathways in fibroblasts. In women with ovarian cancer, levels of a type of T cell called CD8+ were higher in tumours that were more sensitive to cisplatin.

The results suggest that a combination of platinum-based chemotherapies and drugs that boost T-cell responses could be promising against ovarian cancer.

Cell (2016)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

T cells team up with chemotherapy. Nature 533, 11 (2016).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing